Niraparib tosylate

Niraparib Tosylate is a cancer treatment drug that belongs to the class of PARP inhibitors. It is used primarily in the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Mechanism of Action

Niraparib Tosylate works by inhibiting the enzyme PARP, which is involved in DNA repair. By inhibiting this enzyme, the drug prevents cancer cells from repairing their DNA, leading to cell death and slowing or stopping the growth of the tumor.

Uses

Niraparib Tosylate is used to treat adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with certain types of inherited gene mutations (deleterious or suspected deleterious germline BRCA mutations).

Side Effects

Common side effects of Niraparib Tosylate include nausea, fatigue, anemia, thrombocytopenia, and neutropenia. Serious side effects can include hypertension, pneumonitis, and myelodysplastic syndrome.

History

Niraparib Tosylate was approved by the FDA in 2017. It is marketed under the brand name Zejula by Tesaro, a GSK company.

See Also

• PARP inhibitor
• Ovarian cancer
• Fallopian tube cancer
• Peritoneal cancer
• BRCA mutation